Semaglutide (sold under brand names Ozempic and Wegovy) is a GLP-1 receptor agonist. It works by mimicking a hormone that signals fullness to the brain, slows gastric emptying, and improves insulin sensitivity. Clinical trials showed an average weight loss of 15% of body weight over 68 weeks.
Tirzepatide (sold under brand names Mounjaro and Zepbound) is a dual GIP and GLP-1 receptor agonist. By activating two receptors instead of one, tirzepatide may produce greater weight loss for some patients. Clinical trials showed average weight loss of up to 22.5% of body weight.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 only | GLP-1 + GIP |
| Average weight loss | ~15% | ~22.5% |
| Injection frequency | Weekly | Weekly |
| Side effects | Nausea, GI symptoms | Similar, may be slightly lower |
The right choice depends on your health history, current medications, metabolic profile, and weight loss goals. At ThinMD MedSpa in Jacksonville Beach, Dr. Anthony Capasso MD evaluates each patient individually. He reviews your lab work, health history, and goals before recommending a protocol.
ThinMD MedSpa offers physician-supervised semaglutide weight loss and tirzepatide weight loss programs at our Jacksonville Beach and San Jose locations. Call (904) 694-0992 or visit us at 1351 13th Avenue South, Suite 105, Jacksonville Beach, FL.
